A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...
Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
The MHRA reveals a staggering rise in deaths linked to weight loss and diabetes medications in the UK, with concerns over ...
As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Some health experts have call for further investigation, as figures show 82 deaths with suspected links to slimming drugs ...
Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...
Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of ...
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...
The number of teens and young adults taking GLP-1 drugs has increased by 594 percent—but scientists are still trying to ...